Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today...

Related Keywords

Louisiana ,United States ,New Orleans ,American ,Sameem Abedin ,Hans Vitzthum ,Avinash Desai ,Exchange Commission ,American Society Of Hematology ,Ernestm Morial Convention Center ,Lifesci Advisors ,Actinium Pharmaceuticals Inc ,Professor At Froedtert Medical College Wisconsin ,College Of Wisconsin ,Overall Survival ,American Society ,Annual Meeting ,Actinium Pharmaceuticals ,Medical College ,Response Rate ,Assistant Professor ,Medical College Wisconsin ,Principal Investigator ,Chief Medical Officer ,Myeloid Leukemias ,Investigational Therapies ,Excluding Transplantation ,Convention Center ,Elderly Relapsed ,Refractory Acute Myeloid Leukemia ,Looking Statements ,Sci Advisors ,Nc ,